Cellvine Ltd Signs Distribution Agreement with leading US cellular reseller.

Cellvine Ltd., recently announced that it has signed a distribution agreement with Tessco Technologies Incorporated (Nasdaq:TESS). Tessco is a US based provider of integrated product and supply chain solutions for professionals that design, build, run, maintain and use wireless mobile, fixed and in-building systems. Tessco, links customers with integrated product and supply chain solutions configured from product choices made by world-class manufacturers, such as Cellvine Ltd. As part of the agreement, Tessco will range & sell Cellvine’s In-Building Amplifiers & Repeaters.

Cellvine Ltd. offers a broad range of cellular coverage enhancement products and solutions based on the company’s exclusive technology for improving cellular signals for in-building, urban and rural over-ground and subterranean environments such as mines and tunnels. Cellvine’s Comprehensive coverage management tools provide operators with full real-time control of their coverage networks without the need for costly infrastructure replacement.

In 2007, Cellvine continued to show signs of significant growth by securing, together with co-marketing partners Alcatel –Lucent, purchase orders from various Latin American cellular operators. In addition, the company initiated sales in various European and Asia countries and received repeat customer orders from current customers. Moving forward into 2008, the company expects sales momentum to increase as new strategic agreements are inked, new markets opened, repeat sales achieved and continued enhancement & development of market leading technologies. 
More details

Apexum Ltd Completes Recruitment and Treatment of 100 Clinical Study Patients.

Established in 2005, Apexum Ltd. has developed a family of miniature, minimally invasive dental surgical tools, facilitating highly innovative methods for the treatment of Periapical Lesions, associated with root canal infections. The core technology of the company allows the removal of the lesion in a minimally invasive fashion, achieving faster healing kinetics and a better healing rate than standard root canal treatment, without the need for costly and complicated, Apicoectomy operations.

In accordance with FDA requirements, the company recently completed recruitment and treatment of 100 clinical study patients. Interim results from 54 patients with 3 month follow up & 41 patients with 6 month follow up, showed a substantial improvement in both healing kinetics and the healing rate of Periapical lesions compared to conventional root canal treatment – 3 month follow up results indicate there was a 96% healing rate experienced at the study group compared to 32% in the control group. 6 month follow up indicates similar positive results, with a 95% healing rate experienced at the study group compared to 41% in the control group.

Upon the successful completion of the trial, Apexum Ltd. will apply to FDA for approval of their device. Commenting on the current success of the trial, Idan Tobis, General Manager, Apexum Ltd believes that “Apexum Ltd is set to become the new gold standard treatment of Periapical Lesions.”
Read More
 

Neurosonix Ltd receives certificate for EU CE Marking.

Neurosonix Ltd., is an Israeli company that has developed non-invasive ultrasound-based embolic protection technologies for use in cardiac surgery and cath lab practice, for the prevention of Acute Cerebral Embolism. Acute Cerebral Embolism is considered a major source of neurological dysfunction following cardiac surgery and other invasive and minimally invasive procedures.  

The company’s proprietary technology, and first product the Emblocker™, is based on utilizing acoustic forces to manipulate embolic material flowing inside arteries, deflecting it away from vessels supplying blood to harmful locations such as the brain. The technology is efficacious against embolic material composed of solid particles as well as gaseous bubbles.

The company, recently announce that it has received the certificate for  EU CE marking of conformity for the EmBlockerTM V2 and ISO 13485:2003 certification.

In addition to this recent achievement, in 2007, Neurosonix Ltd. was awarded the prestigious European Association of Cardio-Thoracic Surgery Techno-College Innovation Award for, the EmBlocker™. This award was established to honor technological breakthroughs in all areas related to thoracic and cardiovascular research. The award was announced at a ceremony at the Annual Techno-College in Geneva, in front of an audience of over a 1,000 leading cardiac surgeons from around the world. “We are honored that the EACTS has acknowledged the breakthrough we achieved in offering the cardiac surgeons and their patients a unique solution aimed at reducing the risk of brain injury following cardiac surgery”, says Prof. Simcha Milo, inventor of the technology and co-founder of Neurosonix.
More details